Aligos Therapeutics, Inc is a leading biopharmaceutical company based in South San Francisco, CA, dedicated to developing targeted therapies for NASH (nonalcoholic steatohepatitis) and viral diseases. With a strong focus on addressing unmet medical needs, their pipeline consists of potentially groundbreaking drug candidates that target multiple clinically validated mechanisms of action, aiming to provide transformative treatment options for patients worldwide.
Driven by a highly experienced management team, Aligos Therapeutics brings together a group of remarkable individuals with years of expertise in developing therapeutics for chronic liver diseases and viral infections. Their mission is to become a world leader in the field, leveraging their scientific overview and extensive knowledge to create purpose-built, potentially best-in-class small molecule and oligonucleotide drug candidates that target clinically validated mechanisms of action in NASH and viral diseases.
Generated from the website